1. Home
  2. SLRX vs PTIX Comparison

SLRX vs PTIX Comparison

Compare SLRX & PTIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Salarius Pharmaceuticals Inc.

SLRX

Salarius Pharmaceuticals Inc.

HOLD

Current Price

$0.67

Market Cap

3.6M

Sector

Health Care

ML Signal

HOLD

Logo Protagenic Therapeutics Inc.

PTIX

Protagenic Therapeutics Inc.

HOLD

Current Price

$0.77

Market Cap

3.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SLRX
PTIX
Founded
N/A
1994
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.6M
3.0M
IPO Year
N/A
2016

Fundamental Metrics

Financial Performance
Metric
SLRX
PTIX
Price
$0.67
$0.77
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
297.1K
92.7K
Earning Date
11-14-2025
11-26-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.62
$1.12
52 Week High
$108.00
$14.28

Technical Indicators

Market Signals
Indicator
SLRX
PTIX
Relative Strength Index (RSI) 28.77 24.45
Support Level $0.62 $1.12
Resistance Level $0.68 $1.68
Average True Range (ATR) 0.05 0.17
MACD 0.06 -0.01
Stochastic Oscillator 17.86 1.85

Price Performance

Historical Comparison
SLRX
PTIX

About SLRX Salarius Pharmaceuticals Inc.

Salarius Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical needs. The company has focused on two classes of drugs that address gene dysregulation: targeted protein inhibitors and targeted protein degradation. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader.

About PTIX Protagenic Therapeutics Inc.

Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression, and neurodegenerative disorders by using peptide-based and brain-active therapeutics. The company's main compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. It has also created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders.

Share on Social Networks: